<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7038234/results/search/test_trace/results.xml">
  <result pre="mortality. Currently, there are no effective drugs approved for the" exact="treatment" post="of JEV infection. Drug-repurposing screening is an alternative approach"/>
  <result pre="effective drugs approved for the treatment of JEV infection. Drug-repurposing" exact="screening" post="is an alternative approach to discover potential antiviral agents."/>
  <result pre="mortality. Currently, there are no effective drugs approved for the" exact="treatment" post="of JEV infection. Drug-repurposing screening is an alternative approach"/>
  <result pre="effective drugs approved for the treatment of JEV infection. Drug-repurposing" exact="screening" post="is an alternative approach to discover potential antiviral agents."/>
  <result pre="approach to discover potential antiviral agents. In this study, high-content" exact="screening" post="(HCS) of a natural extracts library was performed, and"/>
  <result pre="and digoxin, were identified as having robust efficiency against JEV" exact="infection" post="with the selectivity indexes over 1,000. The results indicated"/>
  <result pre="The results indicated that ouabain and digoxin blocked the JEV" exact="infection" post="at the replication stage by targeting the Na+/K+-ATPase. Furthermore,"/>
  <result pre="work demonstrated that Na+/K+-ATPase could serve as the target of" exact="treatment" post="of JEV infection, and ouabain has the potential to"/>
  <result pre="to be developed as an effective anti-JEV drug. KEYWORDS high-content" exact="screening" post="(HCS) Japanese encephalitis virus (JEV) ouabain digoxin Na+/K+-ATPase Funding"/>
  <result pre="FDA-approved compounds, ouabain and digoxin, were identified to inhibit JEV" exact="infection" post="both in vitro and in vivo. The results of"/>
  <result pre="to contribute to our understanding of the biology of JEV" exact="infection" post="and provide novel host targets for the development of"/>
  <result pre="density of 10,000 cells per 96-well plate, a multiplicity of" exact="infection" post="(MOI) of 0.8, and an endpoint of 24 h"/>
  <result pre="that the assay was robust and reproductive for the large-scale" exact="screening" post="of novel antiviral compounds against JEV infection. HCS assay"/>
  <result pre="infection, an immunofluorescence assay (IFA)-based HCS assay was performed by" exact="screening" post="a library of 1,034 natural extracts for the anti-JEV"/>
  <result pre="1B and C, 851 compounds were selected for the second" exact="screening" post="because of their solubility in dimethyl sulfoxide (DMSO) at"/>
  <result pre="based on this criterion, 23 compounds (2.22%) were selected. A" exact="screening" post="to reconfirm the results was then carried out using"/>
  <result pre="of &amp;gt;1,917 and &amp;gt;969.9, respectively. FIG 1 HCS for inhibitors of JEV" exact="infection" post="using the natural extracts library. (A) HCS assay timeline."/>
  <result pre="and digoxin in different cell lines and viruses. For AT31" exact="infection" post="of Vero cells, digoxin (392 nM) and ouabain (196 nM) displayed"/>
  <result pre="the inhibitory effect of two compounds on AT31 and SA14" exact="infection" post="was also evaluated in Huh-7 cells and U251 cells."/>
  <result pre="lines (Fig. 3G to J). Ouabain and digoxin inhibit JEV" exact="infection" post="during viral RNA synthesis. To determine the cellular process"/>
  <result pre="translation of replicon RNA, confirming that these drugs inhibit JEV" exact="infection" post="at the replication stage. JEV inhibition with ouabain and"/>
  <result pre="mice in the JEV-infected group succumbed to the infection. Ouabain" exact="treatment" post="following JEV infection increased the survival rate to nearly"/>
  <result pre="JEV-infected group succumbed to the infection. Ouabain treatment following JEV" exact="infection" post="increased the survival rate to nearly 60% (8 out"/>
  <result pre="plaque assay on days 7, 10, and 21. (C) Ouabain" exact="treatment" post="alleviated the histopathological changes in mice caused by JEV"/>
  <result pre="results indicated that, during the progression of the disease, ouabain" exact="treatment" post="significantly reduced viral load in infected mice compared to"/>
  <result pre="JEV-infected and vehicle-treated group on day 7 postinfection, while ouabain" exact="treatment" post="remarkably alleviated these phenomena (Fig. 6C). These results indicate"/>
  <result pre="or psychiatric sequelae. Currently, there is no safe and effective" exact="treatment" post="for JEV infection. Recently, Wang et al. performed a"/>
  <result pre="and reported that manidipine, a calcium blocker using in the" exact="treatment" post="of hypertension, inhibited JEV infection in vitro and in"/>
  <result pre="calcium blocker using in the treatment of hypertension, inhibited JEV" exact="infection" post="in vitro and in vivo (11). Similarly, Fang et"/>
  <result pre="drug that targets the peripheral benzodiazepine receptor, reduced the JEV" exact="infection" post="in vitro (15). Drug screening and repurposing has become"/>
  <result pre="benzodiazepine receptor, reduced the JEV infection in vitro (15). Drug" exact="screening" post="and repurposing has become a very useful approach for"/>
  <result pre="check for the ability to inhibit JEV infection. Our high-content" exact="screening" post="assay design could identify compounds that inhibit JEV viral"/>
  <result pre="with similar chemical structures and have been used for the" exact="treatment" post="of cardiac arrhythmias and hypotension for more than 200 years."/>
  <result pre="(26). In this study, ouabain exhibited therapeutic effects on JEV" exact="infection" post="in an adult mouse model by decreasing viral loads"/>
  <result pre="contribute to the antiviral effects. First, ouabain may block JEV" exact="infection" post="by inducing the cellular stress response. Ouabain treatment in"/>
  <result pre="block JEV infection by inducing the cellular stress response. Ouabain" exact="treatment" post="in mammalian cells causes the interaction between the inositol"/>
  <result pre="differentiation, which stimulate an antiviral state that might block JEV" exact="infection" post="in the end (30). Second, JEV could replicate in"/>
  <result pre="of inflammatory cells; the breakdown of BBB caused by JEV" exact="infection" post="may have allowed BBB-nonpermissive ouabain to enter the brain,"/>
  <result pre="the same wells. After an additional 23 h of incubation," exact="infection" post="was stopped by rinsing each well once with phosphate-buffered"/>
  <result pre="for 15 min and blocked with 5% FBS (Gibco), followed by" exact="treatment" post="with the primary antibody anti-JEV prM (full-length prM was"/>
  <result pre="according to the following: preinfection (−1 to 0 h), during" exact="infection" post="(0 to 1 h), and postinfection (1 to 24"/>
  <result pre="for 1 h, and the mixtures were diluted 100-fold before" exact="infection" post="of Vero cells. Virus titers were determined by plaque"/>
  <result pre="at 4°C) for 15 min and then diluted serially prior to" exact="infection" post="of BHK-21 cells. The viral titer was adjusted for"/>
  <result pre="tissue staining. Statistical analysis. Student's t test and log rank" exact="tests" post="were used to evaluate the statistical significance of differences."/>
  <result pre="derivative (SCH 16) is an inhibitor of Japanese encephalitis virus" exact="infection" post="in vitro and in vivo. Virol J5:64. doi:10.1186/1743-422X-5-64.18498627 10.ChangSJ,"/>
  <result pre="doi:10.1128/JVI.01055-17.28814523 12.NawaM, TakasakiT, YamadaK, KuraneI, AkatsukaT2003Interference in Japanese encephalitis virus" exact="infection" post="of Vero cells by a cationic amphiphilic drug, chlorpromazine."/>
 </snippets>
</snippetsTree>
